Practice Impact Extra

Are we underestimating the CV risks?

Another reason to treat to guideline levels.

Should we continue or discontinue statin therapy in elderly patients?

What is the significance if they occur during stress or recovery?

Does treatment alter outcomes?

Does age and risk identify survival experience?

98 Calcium Scoring by AccessCardiology

Do we need to adjust DOAC dosing in the obese?

Are there any updates on stem cell treatment for heart failure?

Can we surgically reduce AF?

Can SGLT2 inhibitor Empagliflozin impact on true normal LVEF and heart failure?

Do we need to change our approach to asymptomatic aortic stenosis treatment?

Is it time to add colchicine to the ACC/AHA guidelines CV treatment?

Is cumulative LDL measurement a stronger risk factor for CV events?

In acute coronary syndrome is a short or long-term DAPT strategy best?

New outcome analysis of CAD burden and CV outcomes

Can a salt substitute reduce stroke?

Is there a target SBP for intensive antihypertensive treatment in the elderly?

HFpEF and benefit to SGLT2 to improve outcomes?

Influenza is a trigger for CV disease. What can be done to reduce complication risk after myocardial infarction?

Recent research to help identify underestimated ASCVD risk individuals.

Persistent HyperTriglycerides: Can the CVD risk be reduced?

Hypertension treatment: ACE or ARB?

Cardiogenic Shock: Is there a "best" inotrope?

Can this experimental MRA reduce atrial fibrillation?

Is DASH the preferred heart-healthy diet?

Reducing Ischemic Stroke.

DAPT post Myocardial infarction. Anything new?

Post TAVR oral anti-coagulation vs. platelet treatment

Does ARNI present an advantage versus ACE inhibition?

Is there an advantage to left atrial appendage closure during cardiac surgery?

Clopidogrel or ASA after DAPT treatment?

Is 325 mg ASA superior to 81 mg ASA for ASCVD?

Prescribing concerns.

Much more to consider.

Do we need advanced lipoprotein testing?

Will the FDA consider an additional treatment indication?

Can a routine ECG diagnose CV disease in diabetic patients?

Can Japanese teas improve survival after stroke and MI?

Can coffee reduce the risk of heart failure?

Can CMR identify heart disease in Covid-19 patients with elevated Troponin?

Should the present guideline targets for hypertension for women be modified?

Can a new SGLT2/1 sotagliflozin reduce CV events?

Is there any additional benefit in outcomes noted for the SGLT2/1 drug Sotagliflozin in improving heart failure outcomes?

Any benefit of Omega 3 fatty acid in the prevention of atrial fibrillation?

Two trials that do not support the routine use of Omega 3 fatty acid in the reduction of cardiovascular events.

Does daily consumption of alcohol offer any heart health benefit?

Can we reduce the progression of left ventricular dysfunction and heart failure?

Can we reduce the rate of cancer therapy related cardiac dysfunction in treated patients?

Can imaging with OCT / CMR better define the ediology of MINOCA?

Pericarditis: Can we reduce the recurrent rate?